| Literature DB >> 29890643 |
Aaron McConville1, Catherine Hegarty2, James Davis3.
Abstract
The increasing devolution of healthcare towards community care has meant that the management of many conditions is conducted within the home either by community nurses or by the patients themselves. The administration of medicines within home healthcare scenarios can however be problematic—especially when considering the delivery of medicines through injection. The possibility of needlestick injury (NSI) has become an ever-present hazard within healthcare settings, with a significant proportion of percutaneous injuries occurring during the handling and disposal of the needle. The emergence of transdermal microneedle systems, however, offers a potentially revolutionary advance and could dramatically improve safety—particularly within home healthcare where there are mounting concerns over the use and disposal of sharps. A mini-review of the advantages proffered by microneedle drug delivery technologies is presented and the potential impact on delivery of medicines within the home is critically appraised.Entities:
Keywords: bloodborne pathogen; microneedle; needlestick; sharps disposal; transdermal
Year: 2018 PMID: 29890643 PMCID: PMC6023334 DOI: 10.3390/medicines5020050
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Figure 1Incidence of needlestick injuries by device type (A), process (B), person (C), and location (D). (Figures adapted from Reference [4]).
Figure 2Sharps disposal practices for healthcare worker- and patient-managed treatment regimes.
Figure 3(A) Comparison of a microneedle patch (200 × 200 × 350 μm) with a standard hollow-bore needle. (B) Electron micrograph of the polystyrene microneedle patch.
Figure 4Mode of action inherent to solid (A), coated (B), hollow (C), dissolvable (D), and swellable (E) microneedle systems. (Reproduced with permission from [29]).
Recent developments in dissolvable/swellable microneedle systems.
| Drug | Polymer | Type | Ref. |
|---|---|---|---|
| Dihydroergotamine mesylate | Polyvinylpyrrolidone | D | [ |
| Thymopentin | Polyvinylpyrrolidone | D | [ |
| Exendin-4 | Carboxymethylcellulose | D | [ |
| Fluorescent Model | Hyaluronic acid/PVA | D | [ |
| Sumatriptan succinate | Polyvinylpyrrolidone | D | [ |
| Adenosine | Hyaluronic acid | D | [ |
| Vitamin K | Gantrez® S-97, a copolymer of methyl vinyl ether and maleic acid | D | [ |
| Lysozyme | Polyvinylpyrrolidone | D | [ |
| Valproic acid | Carboxymethylcellulose | D | [ |
| Besifloxacin | Polyvinylpyrrolidone | D | [ |
| Caffeine/Theophylline | Hydrolysed poly(methyl-vinyl ether-co-maleic anhydride) and poly(ethyleneglycol) | S-E | [ |
| None Specified | Poly(methyl vinyl ether-co-maleic acid) and pectin | S | [ |
| Glucose/Cholesterol | Methacrylated hyaluronic acid | S-E | [ |
| FITC-dextrans | Silk fibroin | S | [ |
| Curcumin | Gantrez® S-97 poly(methyl vinyl ether-co-maleic acid) and Tween 85 | S | [ |
Where: D = dissolving; S = swellable; S-E = swellable extraction of fluid.